Speakers | Kisaco Research

Speakers

The Pharma & Biotech Patent Litigation Summit, Europe
23-24 January, 2024
Anantara Grand Hotel, Amsterdam
  • Author:

    Agathe Michel-De-Cazotte

    Partner
    Carpmaels & Ransford

    Agathe Michel-De-Cazotte

    Partner
    Carpmaels & Ransford
  • Author:

    Andreas Robinson

    Senior Counsel Intellectual Property & Litigation
    Amgen

    Andreas Robinson

    Senior Counsel Intellectual Property & Litigation
    Amgen
  • Author:

    Andrew Hutchinson

    Partner
    Simmons & Simmons

    Andrew Hutchinson

    Partner
    Simmons & Simmons
  • Author:

    Antje Brambrink

    Counsel
    Finnegan

    Dr. Antje Brambrink is qualified and admitted as an attorney at law in Germany. She advises and represents clients in complex patent disputes on all IP-related matters, often at the interface of antitrust and regulatory laws. Her expertise covers various fields of technology with a focus on pharmaceuticals, biotechnology, med-tech, as well as renewable energies and high-tech. Our clients appreciate Antje’s deep understanding of the life sciences sector based on her dual qualification as a licensed dentist.

     

    As a patent litigator, Antje represents clients in infringement, preliminary injunction and inspection proceedings before German district and appeal courts as well as in nullity and compulsory license proceedings at the German Federal Patent Court and the Federal Supreme Court.

     

    In addition to her work as a litigator, Antje advises clients strategically on all issues relating to intellectual property rights (patents, utility models, supplementary protection certificates), such as contracts for the licensing and transfer of rights also in connection with international transactions or the newly established Unified Patent Court (UPC). She has extensive experience in the European coordination of multinational patent disputes.

     

    Prior to joining Finnegan, Antje practiced patent litigation for several years in the patent litigation teams of two international law firms seated in Germany. Antje’s medical and scientific background is of great benefit in advising clients from the life sciences sector. Renowned pharmaceutical, biotechnology and medical devices companies regularly seek her advice. She also advises in the field of renewable energies and in the enforcement of standard-essential patents.

    Antje Brambrink

    Counsel
    Finnegan

    Dr. Antje Brambrink is qualified and admitted as an attorney at law in Germany. She advises and represents clients in complex patent disputes on all IP-related matters, often at the interface of antitrust and regulatory laws. Her expertise covers various fields of technology with a focus on pharmaceuticals, biotechnology, med-tech, as well as renewable energies and high-tech. Our clients appreciate Antje’s deep understanding of the life sciences sector based on her dual qualification as a licensed dentist.

     

    As a patent litigator, Antje represents clients in infringement, preliminary injunction and inspection proceedings before German district and appeal courts as well as in nullity and compulsory license proceedings at the German Federal Patent Court and the Federal Supreme Court.

     

    In addition to her work as a litigator, Antje advises clients strategically on all issues relating to intellectual property rights (patents, utility models, supplementary protection certificates), such as contracts for the licensing and transfer of rights also in connection with international transactions or the newly established Unified Patent Court (UPC). She has extensive experience in the European coordination of multinational patent disputes.

     

    Prior to joining Finnegan, Antje practiced patent litigation for several years in the patent litigation teams of two international law firms seated in Germany. Antje’s medical and scientific background is of great benefit in advising clients from the life sciences sector. Renowned pharmaceutical, biotechnology and medical devices companies regularly seek her advice. She also advises in the field of renewable energies and in the enforcement of standard-essential patents.

  • Author:

    Aoife Murphy

    Partner
    DLA Piper

    Aoife Murphy

    Partner
    DLA Piper
  • Author:

    Arjan Reijns

    Legal Director Amsterdam
    Pinsent Masons

    Arjan Reijns

    Legal Director Amsterdam
    Pinsent Masons
  • Author:

    Arvid van Oorschot

    Partner
    Vondst

    Arvid van Oorschot

    Partner
    Vondst
  • Author:

    Benjamin May

    Partner
    Aramis

    Benjamin May was admitted to practice law in 2000 and further admitted to the panel of “Intellectual Property specialists” with the Bar Association. Practice head of IP at Aramis, Benjamin specializes in cross-border patent litigation with a focus on pharmaceuticals, medical devices and biotechs. The 7 attorneys of the IP team are all internationally trained and address a wide range of patent law matters (e.g. invalidity strategies, infringement, launching at risk, preliminary injunctions, licensing, R&D and consortium agreements). In 2023 the team was ranked amongst the leading patent litigation practices in France, and Benjamin as “leading individual” (Legal 500).

    Benjamin May

    Partner
    Aramis

    Benjamin May was admitted to practice law in 2000 and further admitted to the panel of “Intellectual Property specialists” with the Bar Association. Practice head of IP at Aramis, Benjamin specializes in cross-border patent litigation with a focus on pharmaceuticals, medical devices and biotechs. The 7 attorneys of the IP team are all internationally trained and address a wide range of patent law matters (e.g. invalidity strategies, infringement, launching at risk, preliminary injunctions, licensing, R&D and consortium agreements). In 2023 the team was ranked amongst the leading patent litigation practices in France, and Benjamin as “leading individual” (Legal 500).

  • Author:

    Brian Goldberg

    Counsel
    Dechert

    Brian M. Goldberg is a Counsel in Dechert LLP’s intellectual property practice with a focus on life sciences patent litigation. Mr. Goldberg has successfully litigated patent cases through bench and jury trials, as well as parallel PTAB proceedings, with vast experience litigating Hatch-Waxman Act ANDA infringement actions. Mr. Goldberg has extensive first-hand experience applying the doctrine of equivalents in patent litigations involving small molecule and biologic pharmaceutical products. Mr. Goldberg’s neuroscience background and deep understanding of the statutory and regulatory framework of the Hatch-Waxman Act provides him invaluable insight in litigating cases to achieve successful outcomes for his clients.

    Brian Goldberg

    Counsel
    Dechert

    Brian M. Goldberg is a Counsel in Dechert LLP’s intellectual property practice with a focus on life sciences patent litigation. Mr. Goldberg has successfully litigated patent cases through bench and jury trials, as well as parallel PTAB proceedings, with vast experience litigating Hatch-Waxman Act ANDA infringement actions. Mr. Goldberg has extensive first-hand experience applying the doctrine of equivalents in patent litigations involving small molecule and biologic pharmaceutical products. Mr. Goldberg’s neuroscience background and deep understanding of the statutory and regulatory framework of the Hatch-Waxman Act provides him invaluable insight in litigating cases to achieve successful outcomes for his clients.

  • Author:

    Brian O'Moore

    Honourable Judge
    Irish High Court

    Brian O'Moore

    Honourable Judge
    Irish High Court
  • Author:

    Cecile Goy

    Partner
    Aramis Law

    Cécile Goy is a member of the Paris Bar focusing on international patent litigation, in particular in the life sciences sector. Before joining Aramis, Cécile worked with an international IP boutique and in-house in the legal department of a car manufacturer. Cécile has also completed an internship at the IP section of the Paris Court of Appeal. Cécile is the author of several articles, including on medical devices and digital therapeutics.

    Cecile Goy

    Partner
    Aramis Law

    Cécile Goy is a member of the Paris Bar focusing on international patent litigation, in particular in the life sciences sector. Before joining Aramis, Cécile worked with an international IP boutique and in-house in the legal department of a car manufacturer. Cécile has also completed an internship at the IP section of the Paris Court of Appeal. Cécile is the author of several articles, including on medical devices and digital therapeutics.

  • Author:

    Charles Collins-Chase

    Partner
    Finnegan

    Charles Collins-Chase focuses on district court patent litigation and appeals before the U.S. Court of Appeals for the Federal Circuit, where he served as a clerk. He uses his chemical engineering background to help clients protect innovations in pharmaceuticals and biotechnology, energy and renewables, and chemical products. He has assisted numerous clients in Hatch-Waxman (ANDA) litigation. Charles has handled district court litigations at every stage, from pre-litigation through discovery, dispositive motions, and trial. He particularly enjoys writing briefs and motions.

     

    Charles has extensive experience at the Federal Circuit, where he has argued cases and assisted clients in over two dozen appeals from district courts and the Patent Trial and Appeal Board (PTAB). He has particular experience in appeals involving patent eligibility under 35 U.S.C. § 101. Charles lectures on and has published in several legal and industry media outlets on strategic IP considerations for protecting AI innovations in the pharmaceutical industry.

     

    Before law school, Charles completed an M.Phil. in engineering for sustainable development at the University of Cambridge, where he researched the feasibility of community-scale biodiesel production using a novel reactor system. His undergraduate thesis research involved synthesizing and characterizing thermosetting polymers made from soybean oil and other renewable resources.

     

    Charles also devotes substantial time to pro bono matters and leads the firm’s pro bono committee. He argues before the Federal Circuit on behalf of veterans seeking service-connected disability benefits. He successfully represented a client seeking Social Security disability benefits, writing the briefs and arguing at a hearing before an administrative law judge.

     

    He holds a J.D. (cum laude) from University of Pennsylvania Law School.

    Charles Collins-Chase

    Partner
    Finnegan

    Charles Collins-Chase focuses on district court patent litigation and appeals before the U.S. Court of Appeals for the Federal Circuit, where he served as a clerk. He uses his chemical engineering background to help clients protect innovations in pharmaceuticals and biotechnology, energy and renewables, and chemical products. He has assisted numerous clients in Hatch-Waxman (ANDA) litigation. Charles has handled district court litigations at every stage, from pre-litigation through discovery, dispositive motions, and trial. He particularly enjoys writing briefs and motions.

     

    Charles has extensive experience at the Federal Circuit, where he has argued cases and assisted clients in over two dozen appeals from district courts and the Patent Trial and Appeal Board (PTAB). He has particular experience in appeals involving patent eligibility under 35 U.S.C. § 101. Charles lectures on and has published in several legal and industry media outlets on strategic IP considerations for protecting AI innovations in the pharmaceutical industry.

     

    Before law school, Charles completed an M.Phil. in engineering for sustainable development at the University of Cambridge, where he researched the feasibility of community-scale biodiesel production using a novel reactor system. His undergraduate thesis research involved synthesizing and characterizing thermosetting polymers made from soybean oil and other renewable resources.

     

    Charles also devotes substantial time to pro bono matters and leads the firm’s pro bono committee. He argues before the Federal Circuit on behalf of veterans seeking service-connected disability benefits. He successfully represented a client seeking Social Security disability benefits, writing the briefs and arguing at a hearing before an administrative law judge.

     

    He holds a J.D. (cum laude) from University of Pennsylvania Law School.

  • Author:

    Chris Buntel

    Co-Founder & CIPO
    Tangibly

    Chris Buntel is a US intellectual property attorney with over 20 years experience connecting innovation and intellectual property law. He is a co-founder and the CIPO of Tangibly.  Chris is passionate about trade secrets – the “next big thing” in intellectual property evolution. While other forms of intellectual property have been well supported for years, people are just now realizing the huge need for trade secret management tools and education.  He has a Ph.D. in Organic Chemistry from Stanford University, and J.D. in Law from University of Houston.

    Chris Buntel

    Co-Founder & CIPO
    Tangibly

    Chris Buntel is a US intellectual property attorney with over 20 years experience connecting innovation and intellectual property law. He is a co-founder and the CIPO of Tangibly.  Chris is passionate about trade secrets – the “next big thing” in intellectual property evolution. While other forms of intellectual property have been well supported for years, people are just now realizing the huge need for trade secret management tools and education.  He has a Ph.D. in Organic Chemistry from Stanford University, and J.D. in Law from University of Houston.

  • Author:

    Christine Kanz

    Partner
    Hoyng Rokh Monegier

    Christine Kanz

    Partner
    Hoyng Rokh Monegier
  • Author:

    Christopher Freeth

    Principal Associate
    Gowling WLG

    Christopher Freeth

    Principal Associate
    Gowling WLG
  • Author:

    Clemens Heusch

    Head of Global Disputes and Resolution
    Nokia

    Clemens Heusch

    Head of Global Disputes and Resolution
    Nokia
  • Author:

    Conrad Eckhardt

    Vice President IP
    Biotronik

    Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.

    Conrad Eckhardt

    Vice President IP
    Biotronik

    Conrad practices in the IP field for more than 20 years and gained experience across various industries. Having started with Consumer Products at Procter & Gamble he moved on to Pharmaceuticals at Boehringer Ingelheim and is now active in the medical device field, first as Chief IP Counsel at Leica Biosystems and currently as Chief IP Counsel at Biotronik. Conrad is a European Patent Attorney and a European Patent Litigator and has patent litigation experience in Germany, the USA and China.

  • Author:

    Corinna Sundermann

    Senior Vice President Intellectual Property
    Fresenius Kabi

    Corinna Sundermann

    Senior Vice President Intellectual Property
    Fresenius Kabi
  • Author:

    Daan De Lange

    Partner
    Brinkhof

    Daan De Lange

    Partner
    Brinkhof
  • Author:

    Daniela Kinkeldey

    Partner
    Bird & Bird

    Daniela Kinkeldey

    Partner
    Bird & Bird
  • Author:

    Denis Schertenleib

    Partner
    Schertenleib Avocats

    Denis Schertenleib

    Partner
    Schertenleib Avocats
  • Author:

    Diane Adair

    Senior IP Counsel
    Novartis

    Diane Adair

    Senior IP Counsel
    Novartis
  • Author:

    Doug McCann

    Principal
    Fish & Richardson

    Doug McCann

    Principal
    Fish & Richardson
  • Author:

    Edgar Brinkman

    Honourable Judge
    UPC Local Division Hague

    Mr. Brinkman finished a chemistry degree in 1993, specialising in biochemistry, and law degree in 1995 at Utrecht University in The Netherlands. After joining the bar that same year as a solicitor/barrister in Amsterdam focusing on patents and regulatory affairs, he was appointed judge at the Court of The Hague, IP department in 2002. He became a senior judge in 2007. He has been involved in many patent and other IP cases and speaks regularly on international conferences. He is co-editor of a leading Dutch IP magazine (BIE).

    Edgar Brinkman

    Honourable Judge
    UPC Local Division Hague

    Mr. Brinkman finished a chemistry degree in 1993, specialising in biochemistry, and law degree in 1995 at Utrecht University in The Netherlands. After joining the bar that same year as a solicitor/barrister in Amsterdam focusing on patents and regulatory affairs, he was appointed judge at the Court of The Hague, IP department in 2002. He became a senior judge in 2007. He has been involved in many patent and other IP cases and speaks regularly on international conferences. He is co-editor of a leading Dutch IP magazine (BIE).

  • Author:

    Eleanor Root

    Partner
    Bird & Bird

    Eleanor Root

    Partner
    Bird & Bird
  • Author:

    Eun-Joo Min

    Director
    WIPO Judicial Institute

    Eun-Joo Min

    Director
    WIPO Judicial Institute
  • Author:

    Ewan Nettleton

    Principal IP Counsel, Oncology Litigation
    Novartis Pharma AG

    Ewan Nettleton

    Principal IP Counsel, Oncology Litigation
    Novartis Pharma AG
  • Author:

    Filip De Corte

    Head of IP
    Syngenta

    Filip De Corte is Head of Intellectual Property at Syngenta Crop Protection, leading patent attorneys based in Switzerland, the UK, the US, The Netherlands and China. Filip joined Syngenta on October 1, 2013. Until then, he held the position of Chief IP Counsel Europe at Cargill (2008 – 2013). Before joining Cargill in 2008, he worked in the Johnson & Johnson patent department, working in Beerse with Janssen Pharmaceutica (1991-2004), New Brunswick (2004-2007), and Brussels (2007-2008). Filip has a Ph.D. in organic chemistry, he is a qualified European Patent Attorney and passed the US patent bar exam. He has the qualification of European Patent Litigation from the University of Strasbourg. He also has an MBA of the Vlerick School of Management.  Filip taught patent law in Antwerp under the auspices of CEIPI (Université de Strasbourg) as well as at the University of Leuven in the IPR management course and is a lecturer in the CEIPI patent litigation course.

    Filip De Corte

    Head of IP
    Syngenta

    Filip De Corte is Head of Intellectual Property at Syngenta Crop Protection, leading patent attorneys based in Switzerland, the UK, the US, The Netherlands and China. Filip joined Syngenta on October 1, 2013. Until then, he held the position of Chief IP Counsel Europe at Cargill (2008 – 2013). Before joining Cargill in 2008, he worked in the Johnson & Johnson patent department, working in Beerse with Janssen Pharmaceutica (1991-2004), New Brunswick (2004-2007), and Brussels (2007-2008). Filip has a Ph.D. in organic chemistry, he is a qualified European Patent Attorney and passed the US patent bar exam. He has the qualification of European Patent Litigation from the University of Strasbourg. He also has an MBA of the Vlerick School of Management.  Filip taught patent law in Antwerp under the auspices of CEIPI (Université de Strasbourg) as well as at the University of Leuven in the IPR management course and is a lecturer in the CEIPI patent litigation course.

  • Author:

    Filipe Pedro

    Director of IP
    BIAL

    Filipe Pedro

    Director of IP
    BIAL
  • Author:

    Frank Landolt

    Chief Counsel IP & Legal
    Confo Therapeutics

    Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

    After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands. 

    Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth. 

    From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.

    Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

    Frank Landolt

    Chief Counsel IP & Legal
    Confo Therapeutics

    Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.

    After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands. 

    Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth. 

    From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.

    Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).

  • Author:

    Gaëlle Bourout

    Counsel
    Linklaters

    Gaëlle Bourout

    Counsel
    Linklaters
  • Author:

    Georgia Roussou

    Senior Legal Counsel
    Win Media

    Georgia Roussou

    Senior Legal Counsel
    Win Media
  • Author:

    Guido Pontremoli

    Coporate IP Patent Director
    Chiesi

    Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.

     

    Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.

    Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.

    Guido Pontremoli

    Coporate IP Patent Director
    Chiesi

    Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.

     

    Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.

    Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.

  • Author:

    Hannes Iserentant

    Head of IP
    Ceylad Oncology

    Hannes Iserentant, Head of IP at Celyad Oncology, started his IP career in private practice Bird Goën & Co as member of the Life Sciences team. In 2008, he joined the tech transfer team of VIB, a dedicated life sciences research institute, as IP Manager. From 2013 to 2016, he was part of the Expert Group on patent law in the field of biotechnology for the European Commission. He joined Celyad Oncology in 2016, where he now is Head of IP. Hannes Iserentant holds a PhD in Biomedical Sciences from Ghent University, is a qualified European Patent Attorney and European Patent Litigator.

    Hannes Iserentant

    Head of IP
    Ceylad Oncology

    Hannes Iserentant, Head of IP at Celyad Oncology, started his IP career in private practice Bird Goën & Co as member of the Life Sciences team. In 2008, he joined the tech transfer team of VIB, a dedicated life sciences research institute, as IP Manager. From 2013 to 2016, he was part of the Expert Group on patent law in the field of biotechnology for the European Commission. He joined Celyad Oncology in 2016, where he now is Head of IP. Hannes Iserentant holds a PhD in Biomedical Sciences from Ghent University, is a qualified European Patent Attorney and European Patent Litigator.

  • Author:

    Jako Eleveld

    Head of IP Licensing
    Philips

    Jako Eleveld

    Head of IP Licensing
    Philips
  • Author:

    James Horgan

    Assistant General Counsel
    MSD

    James Horgan

    Assistant General Counsel
    MSD
  • Author:

    Jenny Davies

    Partner
    Gowling

    Jenny Davies is a life sciences and patent specialist with a Masters in Biochemistry from Oxford. She provides strategic advice to help clients protect and exploit their R&D investment in the life sciences sector, medical device sector and the chemical industry. Her work regularly entails negotiating agreements to support her clients' research, development, manufacture and commercialisation, and protect their markets through the enforcement of patents.

     

    Jenny delivers business-focused solutions across her unique practice area spanning patents and dispute resolution, transactions ranging from strategic licensing to highly complex collaborations and regulatory matters. She advises clients in all aspects of patent enforcement, from technical analysis and global strategy to leading UK litigation and EPO oppositions.

     

    Given the commercial and practical value of the assets Jenny protects, her approach combines precision and detail with a commercial mindset and sector-led solutions. Clients praise her "endless determination", "formidable intellect" and are "deeply impressed" with her "unusual capacity to think creatively".

     

    Her work highlights include leading ground-breaking patent litigation up to the UK Court of Appeal to achieve a novel form of "Arrow declaration" for Fujifilm Kyowa Kirin and advising AstraZeneca across a range of high value and complex transactions: its collaboration with the University of Oxford (COVID-19 vaccine); two $6 billion oncology collaborations with Daiichi Sankyo; an $8.5 billion oncology deal with Merck; and a $300 million oncology deal with Genzyme (Caprelsa).

     

    Jenny is a member of the BioIndustry Association's IP Advisory Committee, and SPC and exclusivities committee, and a regular speaker on patent litigation and strategy.

    Jenny Davies

    Partner
    Gowling

    Jenny Davies is a life sciences and patent specialist with a Masters in Biochemistry from Oxford. She provides strategic advice to help clients protect and exploit their R&D investment in the life sciences sector, medical device sector and the chemical industry. Her work regularly entails negotiating agreements to support her clients' research, development, manufacture and commercialisation, and protect their markets through the enforcement of patents.

     

    Jenny delivers business-focused solutions across her unique practice area spanning patents and dispute resolution, transactions ranging from strategic licensing to highly complex collaborations and regulatory matters. She advises clients in all aspects of patent enforcement, from technical analysis and global strategy to leading UK litigation and EPO oppositions.

     

    Given the commercial and practical value of the assets Jenny protects, her approach combines precision and detail with a commercial mindset and sector-led solutions. Clients praise her "endless determination", "formidable intellect" and are "deeply impressed" with her "unusual capacity to think creatively".

     

    Her work highlights include leading ground-breaking patent litigation up to the UK Court of Appeal to achieve a novel form of "Arrow declaration" for Fujifilm Kyowa Kirin and advising AstraZeneca across a range of high value and complex transactions: its collaboration with the University of Oxford (COVID-19 vaccine); two $6 billion oncology collaborations with Daiichi Sankyo; an $8.5 billion oncology deal with Merck; and a $300 million oncology deal with Genzyme (Caprelsa).

     

    Jenny is a member of the BioIndustry Association's IP Advisory Committee, and SPC and exclusivities committee, and a regular speaker on patent litigation and strategy.

  • Author:

    Jiri Slavik

    Director of IP
    Adalvo

    Jiri Slavik

    Director of IP
    Adalvo
  • Author:

    John Cox

    Partner
    Barnes & Thornburg

    With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.


    Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
    John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.

    John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.


    John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.

    John Cox

    Partner
    Barnes & Thornburg

    With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.


    Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
    John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.

    John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.


    John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.

  • Author:

    Julia Schönbohm

    Partner
    Linklaters

    Julia Schönbohm

    Partner
    Linklaters
  • Author:

    Kamleh Nicola

    Partner
    Marks & Clerk

    Kamleh J. Nicola is a leading Canadian patent litigator and health regulatory lawyer who has earned a strong reputation in Canada and internationally. She is a partner at Marks & Clerk Canada and is Co-Head of their Litigation Practice. Kamleh’s specialty is working with domestic and multinational pharmaceutical, biopharma and medtech organizations.  Her technical competency has attracted some of the world’s best-known brands.

    Described by many as tenacious and strategic, she thrives in complex contentious situations across multiple jurisdictions. Kamleh has authored many publications, and presented, on IP, regulatory and compliance subjects focussing on the life science industry

    Kamleh Nicola

    Partner
    Marks & Clerk

    Kamleh J. Nicola is a leading Canadian patent litigator and health regulatory lawyer who has earned a strong reputation in Canada and internationally. She is a partner at Marks & Clerk Canada and is Co-Head of their Litigation Practice. Kamleh’s specialty is working with domestic and multinational pharmaceutical, biopharma and medtech organizations.  Her technical competency has attracted some of the world’s best-known brands.

    Described by many as tenacious and strategic, she thrives in complex contentious situations across multiple jurisdictions. Kamleh has authored many publications, and presented, on IP, regulatory and compliance subjects focussing on the life science industry

  • Author:

    Karin Pramberger

    Intellectual Property Director
    Polpharma Group

    Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

    Karin Pramberger

    Intellectual Property Director
    Polpharma Group

    Karin has been Intellectual Property Director at the Polpharma Group since April 2018. She is responsible for all patent and trade mark related activities. Prior to joining the Polpharma Group, Karin was Head of IP of Medichem, Spain, and worked in various positions within the patent department of Teva, Barr and Pliva.  She spent 7 years in a law firm in Vienna, Austria, where she became European and Austrian patent and trade mark attorney. She studied Biotechnology in Vienna, Austria, and at the Ecole Nationale Supérieure de Chemie de Paris, France. In 2017 she graduated with an LLB from the University of London. Since 2005 she has been a tutor at CEIPI, University of Strasbourg, for the pre-exam and the C-part of the European Qualifying Exam. 

  • Author:

    Kathleen Fox Murphy

    Partner
    EIP

    Kathleen Fox Murphy

    Partner
    EIP
  • Author:

    Katie Coltart

    Partner
    Linklaters

    Katie Coltart

    Partner
    Linklaters
  • Author:

    Kevin Feng

    Patent Attorney/Deputy Chief
    Tsai, Lee & Chen

    Kevin Feng

    Patent Attorney/Deputy Chief
    Tsai, Lee & Chen
  • Author:

    Kit Carter

    Head of IP Litigation
    Sandoz

    Kit Carter

    Head of IP Litigation
    Sandoz
  • Author:

    Kristin Cooklin

    Head of IP
    Zentiva

    Kristin Cooklin

    Head of IP
    Zentiva
  • Author:

    Laila Beynon

    AD- Dispute Resolution
    Regeneron

    Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

    Laila Beynon

    AD- Dispute Resolution
    Regeneron

    Laila Beynon is Director, Dispute Resolution at Regeneron, responsible for the strategic co-ordination of ex-US patent litigation. She has a PhD in Biochemistry/Molecular Biology, 10 years’ private practice experience in life sciences patent litigation at Herbert Smith Freehills LLP, and prior to her role at Regeneron headed up the Patent Litigation team at BAT. 

  • Author:

    Marc Holtorf

    Partner
    Pinsent Masons

    Marc Holtorf

    Partner
    Pinsent Masons
  • Author:

    Marc Lauzeral

    Counsel
    Schertenleib Avocats

    Marc Lauzeral

    Counsel
    Schertenleib Avocats
  • Author:

    Martina Hufnal

    Principal
    Fish & Richardson

    Martina Hufnal

    Principal
    Fish & Richardson
  • Author:

    Mathilde Rauline

    Head of Greater Europe Patent Litigation
    Sanofi

    Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

    She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

    She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

    Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

    Mathilde Rauline

    Head of Greater Europe Patent Litigation
    Sanofi

    Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.

    She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).

    She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.

    Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.

  • Author:

    Maximilian Haedicke

    Honourable Judge
    UPC Central Division Paris

    Maximilian Haedicke

    Honourable Judge
    UPC Central Division Paris
  • Author:

    Michael Swita

    Director of Intellectual Property Policy
    EFPIA

    Michael Swita

    Director of Intellectual Property Policy
    EFPIA
  • Author:

    Michiel De Bruijn

    VP of Sales
    Tangibly

    Michiel De Bruijn

    VP of Sales
    Tangibly
  • Author:

    Mike Cottler

    Ex Global Head of Litigation
    Alvotech

    Mike Cottler

    Ex Global Head of Litigation
    Alvotech
  • Author:

    Mike Gilbert

    Partner
    Marks & Clerk

    Mike Gilbert is a partner at Marks & Clerk in London.  He is an Intellectual Property (IP) lawyer who advises clients in a wide variety of business sectors on issues including litigation and dispute resolution, IP strategy and risk limitation, due diligence projects and commercial and licensing transactions involving IP. His primary focus and expertise, however, lies in life sciences patent litigation where he is considered to be one of the UK’s leading practitioners. He has represented some of the world’s leading biopharmaceutical corporations in complex patent and technical disputes including Genentech, Roche, Chugai, Pfizer, Wyeth, AstraZeneca, MedImmune, Daiichi Sankyo, AbbVie, Amgen and Illumina to name but a few. Mike is well known for his strategic and creative vision and is consistently recommended in various legal directories including the World IP Review, Legal 500, Who's Who Legal and the IAM Patent 1000 guide, which describe him as “always at the top of the pile, especially for pharmaceutical matters”. Mike graduated from Cambridge University in 1989 with a degree in chemical engineering.

    Mike Gilbert

    Partner
    Marks & Clerk

    Mike Gilbert is a partner at Marks & Clerk in London.  He is an Intellectual Property (IP) lawyer who advises clients in a wide variety of business sectors on issues including litigation and dispute resolution, IP strategy and risk limitation, due diligence projects and commercial and licensing transactions involving IP. His primary focus and expertise, however, lies in life sciences patent litigation where he is considered to be one of the UK’s leading practitioners. He has represented some of the world’s leading biopharmaceutical corporations in complex patent and technical disputes including Genentech, Roche, Chugai, Pfizer, Wyeth, AstraZeneca, MedImmune, Daiichi Sankyo, AbbVie, Amgen and Illumina to name but a few. Mike is well known for his strategic and creative vision and is consistently recommended in various legal directories including the World IP Review, Legal 500, Who's Who Legal and the IAM Patent 1000 guide, which describe him as “always at the top of the pile, especially for pharmaceutical matters”. Mike graduated from Cambridge University in 1989 with a degree in chemical engineering.

  • Author:

    Naoise Gaffney

    Vice President - Intellectual Property
    GH Research

    Naoise Gaffney

    Vice President - Intellectual Property
    GH Research
  • Author:

    Naomi Pearce

    CEO and Lawyer
    Pearce IP

    Naomi Pearce is CEO, Executive Lawyer, Patent & Trade Mark Attorney, and Founder of Pearce IP which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards. With a science background in biology, Naomi has been serving life sciences clients for 25 years.  Among other awards, Naomi is 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Award winner (Life Sciences), 2022 Women in Business Law Asia Pacific “Patent Lawyer of the Year”, 2022 Australasian Lawyer “Most Influential Lawyer”, is ranked in IAM Patent 1000, and a MIP “Patent Star”.

    Naomi Pearce

    CEO and Lawyer
    Pearce IP

    Naomi Pearce is CEO, Executive Lawyer, Patent & Trade Mark Attorney, and Founder of Pearce IP which commenced in 2017 and won 2021 “IP Team of the Year” at the Australian Law Awards. With a science background in biology, Naomi has been serving life sciences clients for 25 years.  Among other awards, Naomi is 2023 Lawyers Weekly “IP Partner of the Year”, the 2022 Lexology Client Choice Award winner (Life Sciences), 2022 Women in Business Law Asia Pacific “Patent Lawyer of the Year”, 2022 Australasian Lawyer “Most Influential Lawyer”, is ranked in IAM Patent 1000, and a MIP “Patent Star”.

  • Author:

    Oliver Laing

    Partner
    Potter Clarkson

    Oliver Laing

    Partner
    Potter Clarkson
  • Author:

    Oscar Lamme

    Partner
    Simmons & Simmons

    Oscar Lamme

    Partner
    Simmons & Simmons
  • Author:

    Owen Swens

    Partner
    Vondst

    Owen Swens

    Partner
    Vondst
  • Author:

    Oya Yalvac

    Partner
    DERIS

    Oya is a Turkish and European Patent Attorney with a background in molecular biology and genetics.

    She has worked in the pharmaceutical industry as an in-house patent attorney for more than 10 years.

    She is specialized in patent litigation and freedom to operate analysis.

    Oya Yalvac

    Partner
    DERIS

    Oya is a Turkish and European Patent Attorney with a background in molecular biology and genetics.

    She has worked in the pharmaceutical industry as an in-house patent attorney for more than 10 years.

    She is specialized in patent litigation and freedom to operate analysis.

  • Author:

    Patricia Rombach

    Honourable Judge
    UPC Court of Appeals

    Patricia Rombach

    Honourable Judge
    UPC Court of Appeals
  • Author:

    Paul Inman

    Partner
    Gowling

    With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.

     

    Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.

     

    As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.

     

    Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.

     

    Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.

    Paul Inman

    Partner
    Gowling

    With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.

     

    Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.

     

    As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.

     

    Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.

     

    Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.

  • Author:

    Peter van Schijndel

    Partner
    Hoyng Rokh Monegier

    Peter van Schijndel

    Partner
    Hoyng Rokh Monegier
  • Author:

    Petra Bohanec Grabar

    IP Lead
    Sandoz

    Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg.

    Petra has extensive experience working in house. In her current role as Group Head in Sandoz, Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets.

    Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.

    Petra Bohanec Grabar

    IP Lead
    Sandoz

    Petra Bohanec Grabar is a Slovenian and European Patent Attorney and holds a diploma of Patent Litigation in Europe from the University of Strasbourg.

    Petra has extensive experience working in house. In her current role as Group Head in Sandoz, Petra leads a team of patent practitioners supporting development, in licensing and launch of generic products on global markets.

    Petra holds a PhD in Biochemistry and Molecular Biology from the Faculty of Medicine, University of Ljubljana and is an author of twelve peer reviewed articles in the field of pharmacogenetics.

  • Author:

    Petri Rinkenen

    Honourable Judge
    UPC Helsinki Local Division

    Mr. Petri Rinkinen works as a legally qualified judge in the Unified Patent Court (UPC). He is the presiding judge in the Helsinki local division. He has worked as a judge from September 2013 in the exclusive Finnish IP-court, the Market Court in Helsinki, Finland focusing on IPR-matters, especially to patent cases. Prior to joining the court he has worked as an attorney-at-law since mid 1990’s focusing on IPR-matters. He is a frequent lecturer in IPR-matters. 

    Petri Rinkenen

    Honourable Judge
    UPC Helsinki Local Division

    Mr. Petri Rinkinen works as a legally qualified judge in the Unified Patent Court (UPC). He is the presiding judge in the Helsinki local division. He has worked as a judge from September 2013 in the exclusive Finnish IP-court, the Market Court in Helsinki, Finland focusing on IPR-matters, especially to patent cases. Prior to joining the court he has worked as an attorney-at-law since mid 1990’s focusing on IPR-matters. He is a frequent lecturer in IPR-matters. 

  • Author:

    Pierluigi Perrotti

    Honourable Judge
    UPC Local Division Milan

    Pierluigi Perrotti

    Honourable Judge
    UPC Local Division Milan
  • Author:

    Rae Crisler

    Principal
    Fish & Richardson

    Rae Crisler

    Principal
    Fish & Richardson
  • Author:

    Rebecca Lawrence

    Partner
    DLA Piper

    Rebecca Lawrence

    Partner
    DLA Piper
  • Author:

    Rian Kalden

    Honourable Judge
    UPC Court of Appeal

    Rian Kalden

    Honourable Judge
    UPC Court of Appeal
  • Author:

    Rob Cerwinski

    Partner
    Gemini Law

    Rob Cerwinski

    Partner
    Gemini Law
  • Author:

    Roberto Rodrigues

    Partner
    Licks Attorneys

    Rob Rodrigues manages high-stakes business and IP disputes in Brazil. He assists Fortune 500 and startup companies in matters requiring complex technical ability with a strategic approach, managing patent portfolios of the largest life sciences companies across the globe. His understanding of the Brazilian market makes him a "go-to" lawyer when dealing with enforcement measures. 

     

    Rob earned an LLM from Stanford Law School and is regularly recognized by leading publications like The Legal 500, IAM, and IP Stars, with clients noting that he “combines strong technical skills and a flair for complexity with commercial awareness, pragmatism, and sound judgment.” His clients praise his technical skills, his ability to perform under pressure, and his outstanding leadership in the local community.

    Roberto Rodrigues

    Partner
    Licks Attorneys

    Rob Rodrigues manages high-stakes business and IP disputes in Brazil. He assists Fortune 500 and startup companies in matters requiring complex technical ability with a strategic approach, managing patent portfolios of the largest life sciences companies across the globe. His understanding of the Brazilian market makes him a "go-to" lawyer when dealing with enforcement measures. 

     

    Rob earned an LLM from Stanford Law School and is regularly recognized by leading publications like The Legal 500, IAM, and IP Stars, with clients noting that he “combines strong technical skills and a flair for complexity with commercial awareness, pragmatism, and sound judgment.” His clients praise his technical skills, his ability to perform under pressure, and his outstanding leadership in the local community.

  • Author:

    Sean Alexander

    Head of IP Strategy
    Umicore

    Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.

    Sean Alexander

    Head of IP Strategy
    Umicore

    Sean Alexander is a qualified European Patent Attorney as well as a Canadian and U.S. Patent Agent. He has worked in the IP field for many years and is currently the Head of IP Strategy (H&N) for Chr. Hansen in Denmark. Prior to joining Chr. Hansen, Sean headed the IP team at Elanco Inc. based in the Netherlands and was a Partner with Gowling WLG in Canada. Sean has been recognized as one of the world's leading IP strategists by IAM Magazine and is regularly praised for his pragmatic and commercially aware approach to IP.

  • Author:

    Sergio Napolitano

    General Counsel
    Medicines for Europe

    Sergio Napolitano

    General Counsel
    Medicines for Europe
  • Author:

    Shohta Ueno

    Assistant General Counsel - Dispute Resolution
    Regeneron

    Shohta Ueno

    Assistant General Counsel - Dispute Resolution
    Regeneron
  • Author:

    Stefanie Kies

    Senior Director Intellectual Property
    Polpharma Biologics

    Stefanie Kies

    Senior Director Intellectual Property
    Polpharma Biologics
  • Author:

    Stefan Luginbuehl

    Head of Department European Legal Affairs
    European Patent Office (EPO)

    Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.

    He participated in several Diplomatic and Intergovernmental Conferences on the reform of the European patent system and the international litigation system. He is a lecturer in different universities and is the author and editor of several books and articles on patent procedure and patent litigation in Europe and China.

    Stefan Luginbuehl

    Head of Department European Legal Affairs
    European Patent Office (EPO)

    Stefan Luginbuehl, PhD, lawyer, is Head of the Department European Legal Affairs (Dep 5222) at the European Patent Office where he is dealing with a wide range of patent law and patent litigation related subjects, with emphasis on the implementation of the EU unitary patent package into the existing European patent system.

    He participated in several Diplomatic and Intergovernmental Conferences on the reform of the European patent system and the international litigation system. He is a lecturer in different universities and is the author and editor of several books and articles on patent procedure and patent litigation in Europe and China.

  • Author:

    Sufiyah Sulaiman

    Senior Patent Manager Patent Litigation
    STADA

    Sufiyah Sulaiman is an attorney-at-law with a master’s degree in science. As an in-house patent litigation counsel of generic pharma giants, she has been managing their patent litigation and product launch-at-risk globally. At the moment, she is a senior manager (patent litigation) at STADA (Arzneimittel) AG, before that she was the Global IP litigation counsel for Sandoz (International GmbH) and, IP and regulatory litigation counsel for Mylan (now Viatris). 

    Sufiyah Sulaiman

    Senior Patent Manager Patent Litigation
    STADA

    Sufiyah Sulaiman is an attorney-at-law with a master’s degree in science. As an in-house patent litigation counsel of generic pharma giants, she has been managing their patent litigation and product launch-at-risk globally. At the moment, she is a senior manager (patent litigation) at STADA (Arzneimittel) AG, before that she was the Global IP litigation counsel for Sandoz (International GmbH) and, IP and regulatory litigation counsel for Mylan (now Viatris). 

  • Author:

    Takanori Abe

    Managing Partner
    ABE & PARTNERS

    Mr. ABE is an Attorney-at-Law, admitted in both Japan and New York. He is currently a Guest Professor of Osaka University Graduate School of Medicine and formerly a lecturer of The University of Tokyo Graduate School of Medicine and Faculty of Medicine.  He is an arbitrator in Japan and sit on various positions in Japanese medical/pharmaceutical societies.

    Mr. ABE works in wide areas of international and corporate matters with a focus on intellectual property law and international commerce. The patent litigations that he has participated covers the fields of pharmaceuticals, chemistry, electronics and machinery, which involve advanced technology such as biotechnology, semiconductors, etc., and which are cross-border matters. He has extensive experience on representing and advising multinational and domestic clients in pharmaceutical industry and is currently involved in the drastic battle between brands and also the one between brands and generics. He also has experience in trademark, copyright and unfair competition litigation.

    For Mr. ABE’s detail information and activities, please visit www.abe-law.com or email to: [email protected]

    Takanori Abe

    Managing Partner
    ABE & PARTNERS

    Mr. ABE is an Attorney-at-Law, admitted in both Japan and New York. He is currently a Guest Professor of Osaka University Graduate School of Medicine and formerly a lecturer of The University of Tokyo Graduate School of Medicine and Faculty of Medicine.  He is an arbitrator in Japan and sit on various positions in Japanese medical/pharmaceutical societies.

    Mr. ABE works in wide areas of international and corporate matters with a focus on intellectual property law and international commerce. The patent litigations that he has participated covers the fields of pharmaceuticals, chemistry, electronics and machinery, which involve advanced technology such as biotechnology, semiconductors, etc., and which are cross-border matters. He has extensive experience on representing and advising multinational and domestic clients in pharmaceutical industry and is currently involved in the drastic battle between brands and also the one between brands and generics. He also has experience in trademark, copyright and unfair competition litigation.

    For Mr. ABE’s detail information and activities, please visit www.abe-law.com or email to: [email protected]

  • Author:

    Thierry Lautier

    Partner
    Bird & Bird

    Thierry Lautier

    Partner
    Bird & Bird
  • Author:

    Tjibbe Douma

    Partner, IP, Amsterdam
    Bird & Bird

    Tjibbe Douma

    Partner, IP, Amsterdam
    Bird & Bird
  • Author:

    Toni Santamaria

    Vice President Intellectual Property
    Adalvo

    Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries.   He also has experience in patent and trademark prosecution.

    Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.

    Toni Santamaria

    Vice President Intellectual Property
    Adalvo

    Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries.   He also has experience in patent and trademark prosecution.

    Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.

  • Author:

    Wioletta Niwinska

    Legal Counsel
    Sano

    Wioletta Niwińska is a qualified Polish Attorney, well-versed advising clients on legal issues in all aspects of business operations including IP protection, particularly in the new technologies industry, including AI, machine learning, MedTech. She has gained experience working in international and national law firms, the public sector (at the National Centre for Research and Development) and the private sector, however, she decided to work closer to people. She enjoys working with high-growth start-ups and SMEs, helping them develop their innovative ideas in a legally secure environment. Working with creative people motivates her to continuously develop and explore AI and innovation.

    Wioletta Niwinska

    Legal Counsel
    Sano

    Wioletta Niwińska is a qualified Polish Attorney, well-versed advising clients on legal issues in all aspects of business operations including IP protection, particularly in the new technologies industry, including AI, machine learning, MedTech. She has gained experience working in international and national law firms, the public sector (at the National Centre for Research and Development) and the private sector, however, she decided to work closer to people. She enjoys working with high-growth start-ups and SMEs, helping them develop their innovative ideas in a legally secure environment. Working with creative people motivates her to continuously develop and explore AI and innovation.

  • Author:

    Wouter Pors

    Partner
    Bird and Bird

    Wouter Pors

    Partner
    Bird and Bird
  • Author:

    Zack Mummery

    Partner
    Reddie & Grose

    Zack is a partner at Reddie & Grose and is a UK and European patent attorney based in London.

    Zack assists large multinational corporations, SMEs and start-ups operating at the cutting edge of chemistry and pharmaceutical technologies.  

    Zack has a wealth of experience drafting new patent applications and managing large patent portfolios covering developed and emerging markets. Zack regularly provides clear commercially focussed advice on global patent strategies, utilising patent protection and managing the risk posed by third party patent rights.

    Zack also has experience supporting clients through funding rounds, assisting clients with investor due diligence and he has provided IP support for a number of large deals including a multimillion dollar public offering.

    Zack Mummery

    Partner
    Reddie & Grose

    Zack is a partner at Reddie & Grose and is a UK and European patent attorney based in London.

    Zack assists large multinational corporations, SMEs and start-ups operating at the cutting edge of chemistry and pharmaceutical technologies.  

    Zack has a wealth of experience drafting new patent applications and managing large patent portfolios covering developed and emerging markets. Zack regularly provides clear commercially focussed advice on global patent strategies, utilising patent protection and managing the risk posed by third party patent rights.

    Zack also has experience supporting clients through funding rounds, assisting clients with investor due diligence and he has provided IP support for a number of large deals including a multimillion dollar public offering.